Phase III trial of zanidatamab in biliary tract cancers produces positive topline data

Tecvayli + Darzalex Faspro achieves 100% MRD negativity in newly diagnosed MM, phase II study shows

An investigational immune-based induction regimen with Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) demonstrated meaningful clinical efficacy in transplant-eligible patients with newly diagnosed multiple myeloma.

September 26, 2025

Vol.51 No.35

In Brief

City of Hope expands clinical trial access across U.S. with new national model

City of Hope launched a national clinical trials model to expand access to emerging life-saving cancer treatments to more patients across the country.

September 19, 2025

Vol.51 No.34

Clinical Roundup

Libtayo + chemo shows significant improvement in OS for advanced NSCLC, phase III EMPOWER-Lung 3 trial shows

Libtayo (cemiplimab) plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone, according to late-breaking data from exploratory analyses at World Conference on Lung Cancer.

September 19, 2025

Vol.51 No.34

Clinical Roundup

Rezatapopt monotherapy shows confirmed responses of eight solid tumor types in PYNNACLE phase II clinical trial

Rezatapopt monotherapy generated a 33% overall response rate in 97 patients with solid tumors spanning across eight different cancers (ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma) and a median duration of response of 6.2 months, according to PYNNACLE phase II clinical trial interim data. These were patients whose tumors were TP53 Y220C mutated and KRAS wild-type.

September 19, 2025

Vol.51 No.34

Clinical Roundup

Cancer cells can use backup routes to fuel their growth, Van Andel Institute study finds

When it comes to their survival, cancer cells have a host of backup plans.

September 19, 2025

Vol.51 No.34

Drugs & Targets

VieCure, N-Power Medicine partner to expand clinical trial access in community oncology

N-Power Medicine, an oncology drug development company, and VieCure, a company focused on AI-powered oncology intelligence, have announced a partnership to bring N-Power Medicine’s proprietary Kaleido Registry to the VieCure network.

September 19, 2025

Vol.51 No.34

Phase III trial of zanidatamab in biliary tract cancers produces positive topline data

YOU MAY BE INTERESTED IN

Tecvayli + Darzalex Faspro achieves 100% MRD negativity in newly diagnosed MM, phase II study shows

City of Hope expands clinical trial access across U.S. with new national model

Libtayo + chemo shows significant improvement in OS for advanced NSCLC, phase III EMPOWER-Lung 3 trial shows

Rezatapopt monotherapy shows confirmed responses of eight solid tumor types in PYNNACLE phase II clinical trial

Cancer cells can use backup routes to fuel their growth, Van Andel Institute study finds

VieCure, N-Power Medicine partner to expand clinical trial access in community oncology

Renew today!

Subscriber content

Never miss an issue!

Login